Recombinant Human FCRL3/FcRH3 His-tag Protein, CF

Measured by its binding ability in a functional ELISA. When Recombinant Human FCRL3/FcRH3 His-tag Protein (Catalog # 3126-FCB) is immobilized at 2.00 μg/mL (100 μL/well), Normal Human IgG binds with an ED50 of 1.00‑6.00 μg/mL.

2 μg/lane of Recombinant Human FCRL3/FcRH3 His-tag Protein (Catalog # 3126-FCB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 70-90 kDa.

• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human FCRL3/FcRH3 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human FCRL3/FcRH3 His-tag (Catalog # 3126-FCB) is immobilized at 2.00 μg/mL (100 μL/well), Normal Human IgG binds with an ED₅₀ of 1.00-6.00 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human FCRL3/FcRH3 protein
  Arg14-Arg569, with a C-terminal 6-His tag
• Accession #: Q96P31.1
• N-terminal Sequence: Arg14
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 62 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 70-90 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human FCRL3/FcRH3 His-tag Protein, CF

• CD307c
• Fc receptor homolog 3
• Fc receptor-like 3
• Fc receptor-like protein 3
• FcRH3
• FCRL3
• fcR-like protein 3
• hIFGP3
• IFGP3
• immunoglobulin superfamily receptor translocation associated protein 3
• IRTA3
• SPAP2

Background

FCRL3 (Fc Receptor-Like 3), also known as FcRH3, IRTA3, and SPAP2, is a 110 kDa molecule with sequence homology to classical Fc receptors. The type 1 transmembrane FCRL proteins contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation (1). Mature human FCRL3 consists of a 556 amino acid (aa) extracellular domain (ECD) with six Ig-like domains, a 21 aa transmembrane segment, and a 140 aa cytoplasmic domain with four immunotyrosine inhibitory motifs (ITIMs) (2 - 4). Within the ECD, human and mouse FCRL3 share 35% aa sequence identity. Alternate splicing generates several additional isoforms with deletions or substitutions in both the extracellular and intracellular regions. These include potentially secreted forms that are truncated following the second Ig-like domain (4). FCRL3 is expressed in secondary lymphoid organs on the surface of mature naïve and memory B cells, NK cells, and B cell lines derived from chronic lymphocytic leukemias (2, 3, 5). It is upregulated on B cells following LPS or anti-CD40 stimulation (6). A polymorphism in the FCRL3 promoter induces enhanced transcription and is associated with the development of autoimmune disorders in a Japanese population (6, 7). Tyrosine phosphorylation within the ITIMs of FCRL3 enables its association with SHP-1 (4).

1. Davis, R.S. (2007) Annu. Rev. Immunol. 25:525.
2. Miller, I. et al. (2002) Blood, 99:2662.
3. Davis, R.S. et al. (2001) Proc. Natl. Acad. Sci. 98:9772.
4. Xu, M.-J. et al. (2002) Biochem. Biophys. Res. Commun. 293:1037.
5. Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
6. Kochi, Y. et al. (2005) Nat. Genet. 37:478.
7. Chistiakov, D.A. and A.P. Chistiakov (2007) Hum. Immunol. 68:375.

Publications for FCRL3/FcRH3 (3126-FCB)(3)

Publications using 3126-FCB

• J Vondrakova, M Frolikova, L Ded, J Cerny, P Postlerova, V Palenikova, O Simonik, Z Nahacka, K Basus, E Valaskova, R Machan, A Pacey, Z Holubcova, P Koubek, Z Ezrova, S Park, R Liu, R Partha, N Clark, J Neuzil, M Ikawa, K Erickson, KS Lam, H Moore, K Komrskova MAIA, Fc receptor-like 3, supersedes JUNO as IZUMO1 receptor during human fertilization Science Advances, 2022-09-07;8(36):eabn0047. 2022-09-07 [PMID: 36070373] (Bioassay, Human)
• S Agarwal, Z Kraus, J Dement-Bro, O Alabi, K Starost, M Tolnay Human Fc Receptor-like 3 Inhibits Regulatory T Cell Function and Binds Secretory IgA Cell Rep, 2020-02-04;30(5):1292-1299.e3. 2020-02-04 [PMID: 32023449] (Surface Plasmon Resonance (SPR, Human)
• Franco A, Damdinsuren B, Ise T, Dement-Brown J, Li H, Nagata S, Tolnay M Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol, 2013-04-24;190(11):5739-46. 2013-04-24 [PMID: 23616577] (Surface Plasmon Resonance (SPR, Human)

Bioinformatics

• Uniprot:
  • Q96P31.1()